A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab
Phase 2
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Colorectal Neoplasms
Both
Colorectal Neoplasms
Trial Information
A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And A Fluoropyrimidine, With And Without Bevacizumab
Inclusion Criteria:
- Metastatic colorectal cancer
- Failed selected cancer therapies in the past.
Exclusion Criteria:
- Prior treatment with tyrosine kinase inhibitors or VEGF inhibitors other than
bevacizumab.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Anti-tumor efficacy
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
United States: Food and Drug Administration
Study ID:
A6181003
NCT ID:
NCT00077987
Start Date:
December 2003
Completion Date:
April 2005
Related Keywords:
- Colorectal Neoplasms
- Neoplasms
- Colorectal Neoplasms
Name | Location |
|---|
